Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.55 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22539941 | 1.00 | FOLH1 (0.55) | FOLH1NOD1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL19633812 | 0.86 | FOLH1 (0.66) | FOLH1NOD1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL8639355 | 0.83 | SLC6A5 (0.55) | FOLH1NOD1CTSK | |
| SCHEMBL17509712 | 0.83 | SLC6A5 (0.55) | FOLH1NOD1CTSK | |
| SCHEMBL21162263 | 0.83 | FOLH1 (0.66) | FOLH1NOD1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL10036530 | 0.81 | NOD1 (0.53) | FOLH1NOD1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL16124659 | 0.81 | NOD1 (0.53) | FOLH1NOD1RIMKLANAALAD2PLA2G2C | |
| SCHEMBL20073443 | 0.80 | FOLH1 (0.70) | FOLH1NOD1RIMKLANAALAD2 | |
| SCHEMBL29330184 | 0.80 | FOLH1 (0.70) | FOLH1NOD1RIMKLANAALAD2 | |
| SCHEMBL27098163 | 0.80 | FOLH1 (0.70) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-9301923-B2 | Lipids, lipid compositions, and methods of using them | NOVARTIS AG (CH) | 2016-04-05 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110200582-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | FOLH1 619/4885NOD1 3554/4885RIMKLA 3671/4885 |
| US-20140309277-A1 | LIPIDS, LIPID COMPOSITIONS, AND METHODS OF USING THEM | SGMS1, SGMS2, LIPC | FOLH1 619/4885NOD1 3554/4885RIMKLA 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.